The study of peculiarities of immunotropic action of statins in chronic heart failure of various etiology

Kardiologiya

Volumn 49, Issue 4, 2009, Pages 29-36

  Zykov, K A ^a   Tatenkulova, S N ^a   Mareev, V Yu ^a   Masenko, V P ^a   Balakhonova, T V ^a   Tripoten, M I ^a   Kaznacheeva, E I ^a   Belyavsky, E A ^a   Tkachev, G A ^a   Belenkov, Yu N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Chronic heart failure; Cytokines; Dilated cardiomyopathy; Immune disturbances; Ischemic heart disease; Left ventricular and endothelial dysfunction; Statins

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNITY; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; CARDIOMYOPATHY, DILATED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY; IMMUNOGLOBULINS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 67649397738     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Smith W. Epidemiology of congestive heart failure. Am J Cardiol 1985; 55: 3A-8A. (Pubitemid 15189931)
2. Czuriga I. Chronic heart failure - the epidemic of the 21st century. Orv Hetil 2005; 146 (SUPPL. 2):1075-1087. (Pubitemid 46118701)
3. Kosmala W., Derzhko R., Przewlocka-Kosmala M. et al. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 2008; 19: 375-382.
4. Rugina M., Cams I., Jurcut R. et al. Systemic inflammatory markers in patients with aortic sclerosis. Roum Arch Microbiol Immunol 2007; 66: 10-16.
5. Gotsman I., Stabholz A., Planer D. et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J 2008; 10: 494-498.
6. Greig D., Castro P., Gabrielli L. et al. (Inflammation and endothelial dysfunction in patients with chronic heart failure) Rev Med Chil. 2008; 136: 687-693.
7. Yamaoka-Tojo M., Tojo T., Inomata T. et al. Circulating levels of interleukin 18 reflect etiologies of heart failure: Thl/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail 2002; 8: 21-27. (Pubitemid 34163846)
8. Rivera M., Taléns-Visconti R., Jordán A. et al. [Myocardial remodeling and immunologic activation in patients with heart failure) Rev Esp Cardiol 2006; 59: 911-918.
9. Vanderheyden M., Paulus W.J., Voss M. et al. Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 2005; 91: 926-931. (Pubitemid 40874083)
10. Gullestad L., Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C-23C; discussion 38C-40C. (Pubitemid 40755514)
11. Sola S., Mir M.Q., Lerakis S. et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-337. (Pubitemid 43063250)
12. Dickinson M. G., Ip J.H., Olshansky B. et al. SCD-HeFT Investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007; 153: 573-578. (Pubitemid 46440697)
13. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402. (Pubitemid 32001026)
14. Crisby M., Nordin-Fredriksson G., Shah P.K. et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metaloproteinases, and cell death in human carotid plaques. Implications for stabilization. Circulation 2001; 103: 926-933. (Pubitemid 32183796)
15. Ridker P.M., Danlelson E., Fonseca F.A.H. et al. for the JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. Published at www.nejm.org November 9, 2008 (10.1056/NEJMoa0807646).
16. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HFtrial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Aug 29.
17. Athyros V.G, Kakaflka A.I., Tziomalos K. et al. CORONA, statins, and heart failure: who lost the crown? 1: Angiology 2008; 59: 5-8. (Pubitemid 351253084)
18. Guyatt G.H., Sulivan M.J., Thompson P.J. et al. The 6-minute walk: a new measureof exercise capacity in patients with chronic heart failure. Can Med Assos J 1985; 132: 919-923.
19. Grube M., Köck K, Oswald S. et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80: 607-620. (Pubitemid 44920223)
20. Ndrepepa G., Kastrati A., Braun S. et al. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med 2006; 119: 355. e1-8.
21. Shlipak M.G., Ix J.H., Bibbins-Domingo K. et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008; 121: 50-57.
22. Sánchez Muñoz-Torrero J.F, Crespo Rincón L., Fernández Pereira L. et al. (Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension) Med Clin (Bare) 2006; 127: 521-525.
23. Stefanadi E., Tousoulis D., Antoniades C. et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int J Cardiol 2008 Jan 8.
24. Bimer CM., Ulucan C, Fredersdorf S. et al. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. Cytokine 2007; 40: 89-97. (Pubitemid 350180525)
25. Suzuki H., Sato R., Sato T. et al. Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. Int J Cardiol 2005; 28: 100: 415-420.
26. Schwedler S.B., Kuhlencordt P.J., Ponnuswamy P.P. et al. Native C-reactive protein induces endothelial dysfunction in ApoE-/-mice: implications for iNOS and reactive oxygen species. Atherosclerosis. 2007; 195: e76-84. (Pubitemid 350087981)
27. Schwartz R., Osborne-Lawrence S., Hahner L. et al. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007; 100: 1452-1459. (Pubitemid 46834757)
28. Stumpf C, Seybold K., Petzi S. et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail 2008; 10: 733-739.
29. Stumpf C, Petzi S., Seybold K. et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats afteracute myocardial infarction. Clin Sci (Lond) 2008 May 6.
30. Heeschen C, Dimmeier S., Hamm C.W. et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-2114. (Pubitemid 36532192)
31. Hummelshoj L., Ryder L.P., Poulsen L.K. The role of the interleukin-10 subfamily members in immunoglobulin production by human B cells. Scand J Immunol 2006; 64: 40-47. (Pubitemid 44195101)
32. Wang M., Markel TA, Meldrum D.R. Interleukin 18 in the heart. Shock 2008; 30: 3-10.
33. Jawień J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 2008; 118: 127-131. (Pubitemid 351488259)
34. Eslick G.D., Thampan B.V., Nabs M. et al. Circulating interleukin-18 concentrations and a loss-of-function P2×7 polymorphism in heart failure. Int J Cardiol 2008 Aug 2.
35. Souza K.L., Gurgul-Convey E., Eisner M., Lenzen S. Interaction between pro-inflammatory and anti-inflammatory cytokines in insulin-producing cells. J Endocrinol 2008; 197: 139-150. (Pubitemid 351566933)
36. Sharma J.N., AI-Omran A., Parvathy S.S. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007; 15: 252-259. (Pubitemid 351196133)
37. Guilliomc M., Movahedi K., Bosschaerts T. et al. IL-10 dampens TNF/ inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol 2009; 182: 1107-1118.
38. Hong J. Y., F Sato E., Hiramoto K. et al. Mechanism of Liver Injury during Obstructive Jaundice: Role of Nitric Oxide, Splenic Cytokines, and Intestinal Flora. J Clin Biochem Nutr 2007; 40: 184-193. (Pubitemid 46984211)
39. Korhonen R., Kosonen O., Hämäläinen M., Moilanen E. Nitric oxide-releasing compounds inhibit the production of interleukin-2, -4 and -10 in activated human lymphocytes. 1: Basic Clin Pharmacol Toxicol 2008; 103: 322-328.
40. Fritsche G, Nairz M., Werner E.R et al. Nrampl-functionality increases iNOS expression via repression of IL-10 formation. Eur J Immunol 2008; 38: 3060-3067.
41. Heeba G., Hassan M.K., Khalifa M., Malinski T. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol 2007; 50: 391-398. (Pubitemid 350303816)
42. Hsu H. Y., Wang P. Y., Chen Y. T. et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients. J Chin Med Assoc. 2005; 68: 53-58.
43. Lee S.J., Qin H, Benveniste E.N. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 2008; 38: 2325-2336.
44. Scandinavian Simvastatin Survival Study Group. Randomized trail of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (SSSS) Lancet 1994; 344: 1383-1389.
45. Sacks F.M., Pfeffer MA, Moye L.A. et al. for the Cholesterol and Reccurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infartion in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009. (Pubitemid 26338729)
46. The Long-Term Invervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
47. Shepherd J., Cobbe S.M., Ford I. et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
48. Downs J. R., Clearfield M., Web S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.